Compare
ArriVent BioPharma, Inc. vs Rocket Pharmaceuticals, Inc. vs Liquidia Corp vs ARS Pharmaceuticals, Inc.
| Latest fiscal year | ArriVent BioPharma, Inc. AVBP | Rocket Pharmaceuticals, Inc. RCKT | Liquidia Corp LQDA | ARS Pharmaceuticals, Inc. SPRY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $158.32M | $84.28M |
| Revenue growth (YoY) | n/a | n/a | n/m | -5.5% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | -32.5% | -212.9% |
| Net margin | n/a | n/a | -43.5% | -203.3% |
| Net income | -$166.31M | -$223.12M | -$68.92M | -$171.30M |
| EPS (Diluted) | -$4.32 | -$2.01 | -$0.80 | -$1.74 |
| Operating cash flow | -$160.59M | -$190.01M | -$35.69M | -$170.87M |
| Free cash flow | n/a | -$190.45M | -$40.02M | -$171.21M |
| Cash & equivalents | $45.54M | $77.56M | $190.68M | $41.32M |
| Total assets | $333.17M | $330.45M | $327.93M | $327.65M |
| Total liabilities | $25.95M | $53.23M | $283.19M | $213.39M |
| Shareholders' equity | $307.22M | $277.22M | $44.75M | $114.26M |
| Return on year-end equity | -54.1% | -80.5% | -154.0% | -149.9% |
| Shares outstanding | 42.45M | 108.32M | 87.20M | 99.29M |
Revenue, most recent five fiscal years
| Fiscal year | ArriVent BioPharma, Inc. | Rocket Pharmaceuticals, Inc. | Liquidia Corp | ARS Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2025-12-31 | $158.32M Ended 2025-12-31 | $84.28M Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | $14.00M Ended 2024-12-31 | $89.15M Ended 2024-12-31 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $17.49M Ended 2023-12-31 | $30.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $0 Ended 2022-12-31 | $15.94M Ended 2022-12-31 | $1.32M Ended 2022-12-31 |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | $12.85M Ended 2021-12-31 | $5.51M Ended 2021-12-31 |